43rd week of 2008 patent applcation highlights part 42 |
Patent application number | Title | Published |
20080260783 | COMPOSITION AND METHOD FOR CONTROLLING INTESTINAL PATHOGENIC ORGANISMS - An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild | 2008-10-23 |
20080260784 | Compositions and Methods for Modulating an Immune Response - The present invention provides a composition for suppressing an inflammatory immune response comprising the excretory/secretory (ES) component of | 2008-10-23 |
20080260785 | PAROXETINE COMPOSITIONS - The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered dose. | 2008-10-23 |
20080260786 | Process for making encapsulated particles - Method for preparing an active-containing starch matrix and the free flowing, dry powder that results from such a process. The active ingredients can be released (deposited) onto a surface by normal triggering mechanisms, which include the action of a liquid or by friction or rubbing. The fixative systems described herein provide the ability to control high load levels and protection of the active while still being able to delivery this to a substrate when triggered. Additionally, ingredients incompatible and reactive with each other can be blended together as sold/used as a one piece system and no reactions will occur until the matrix is broken or triggered. | 2008-10-23 |
20080260787 | Use of Collagen in Combination With Oxygen- and Ozone-Releasing Perfluorocarbons For the Preparation of a Medicament For the Treatment of Skin Lesions - A medicament and a medication for the treatment of skin lesions are disclosed, which comprise collagen and an oxygen-carrying and releasing fluorinated hydrocarbon and, optionally and preferably additionally, ozone. Particularly, the invention relates to a kit for the topical administration of such a medicament on the damaged skin, as well as to a process for preparing the medication. | 2008-10-23 |
20080260788 | Skin Cleaning Composition - The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method of manufacturing same. | 2008-10-23 |
20080260789 | Insecticidal polypeptides and methods of use thereof - A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera | 2008-10-23 |
20080260790 | Plasmid Enhancement Agent for High Intensity Focused Ultrasound Treatment and Use Thereof - The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the enhancement agent comprises a discontinuous phase is comprised of a core material encapsulated by a membrane-forming material, and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and has a particle size ranging from 10-1000 nm; the amount of the membrane-forming material in the enhancement agent is 0.1-100g/L; and the core material comprises nanometer-sized biocompatible solid selected from the group consisting of magnetic biomaterials, hydroxylapatite, and calcium carbonate, and the amount of the core material in the enhancement agent is 0.1-150 g/L. | 2008-10-23 |
20080260791 | Injectable capsaicin - The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg. | 2008-10-23 |
20080260792 | Method to Use Therapeutic Microencapsulation of Embedding Parathyroid Live Cells with Theracyte - A method to use a therapeutic microencapsulation of embedding parathyroid live cells with a TheraCyte comprises the steps of: (1) containing the parathyroid live cells in −179° C. liquid nitrogen and then unfrozen for preparing the therapeutic microencapsulation; (2) embedding at least 4×10 | 2008-10-23 |
20080260793 | POROUS GELATIN MATERIAL, GELATIN STRUCTURES, METHODS FOR PREPARATION OF THE SAME AND USES THEREOF - The present invention relates to a porous gelatin material in the form of spherical particles with a continuous pore structure and cast, three-dimensional, porous gelatin structures. The invention also comprises methods for preparation of the porous gelatin materials and structures. The method for preparing the porous gelatin material in the form of spheres with a continuous pore structure comprises the steps of preparing a homogenous water-based gelatin solution, adding an emulsifier with an HLB value >9, adding a first composition comprising an organic solvent and an emulsifier with an HLB value >9, adding a second composition comprising an organic solvent and an emulsifier with an HLB value <8 and allowing the gelatin material to solidify. Uses of the materials according to the invention are also included. | 2008-10-23 |
20080260794 | COLLAGEN PRODUCTS AND METHODS FOR PRODUCING COLLAGEN PRODUCTS - Medical implants and methods for forming a medical implant blends a dispersion of human collagen fibers and/or threads and optionally a volume between about 2 to about 15% of an alcohol and forms medical implants by removing a liquid component of the collagen dispersion. Medical implants formed include collagen films, coatings, threads, patches, tubes, plugs, scaffolds, injectable collagen, and collagen for in vitro applications. | 2008-10-23 |
20080260795 | STRONG REVERSIBLE HYDROGELS - The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical performance and function and are especially suitable for biomedical applications. | 2008-10-23 |
20080260796 | REDUCTION OF INFECTION ASSOCIATED WITH MEDICAL DEVICE - Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective. | 2008-10-23 |
20080260797 | METHODS OF TREATING DISEASE WITH NITRIC OXIDE (NO)-RELEASING POLYMERS AND SOLUBLE NO-RELEASING NITROSAMINES - The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release of NO for the treatment of diseases and disorders associated with NO-deficiency, wherein the treatment includes systemic or local administration of the NO-releasing polymers or the low molecular weight NO-releasing compounds. | 2008-10-23 |
20080260798 | ALIGNED SCAFFOLDS FOR IMPROVED MYOCARDIAL REGENERATION - The present invention relates to a biocompatible, three-dimensional scaffold useful to grow cells and to regenerate or repair tissue in predetermined orientations. The scaffold is particularly useful for regeneration and repair of cardiac tissue. The scaffold contains layers of alternating A-strips and S-strips, wherein the A-strips within each layer are aligned parallel to each other and preferentially promote cellular attachment over attachment to the S-strips. Methods of producing and implanting the scaffold are also provided. | 2008-10-23 |
20080260799 | BIOACTIVE IMPLANT AND METHOD OF USE - The invention relates to a method for producing bioactive implant surfaces consisting of metallic or ceramic materials, to be used for implants such as artificial joints or very small implants such as so-called stents. The invention also relates to implants produced according to this method and methods of using the implants. | 2008-10-23 |
20080260800 | EXTRACELLULAR MATRIX CANCER VACCINE ADJUVANT - Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials. | 2008-10-23 |
20080260801 | COMPOSITE MATERIAL, ESPECIALLY FOR MEDICAL USE, AND METHOD FOR PRODUCING THE MATERIAL - A biocompatible, resorbable composite material having good mechanical properties, and can be populated by cells is provided comprising | 2008-10-23 |
20080260802 | Biocompatible hydrogels made with small molecule precursors - Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers. Embodiments that include hydrogels having isolated hydrolytically degradable esters are set forth. Embodiments including the use of low molecular weight amines to make degradable hydrogels are also set forth. | 2008-10-23 |
20080260803 | SUSTAINED RELEASE INTRAOCULAR INPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS - Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions. | 2008-10-23 |
20080260804 | Medical devices having antimicrobial coatings thereon - The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial, a low toxicity, low coefficient of friction, and increased hydrophilicity while maintaining the desired bulk properties such as oxygen permeability and ion permeability of lens material. Such lenses are useful as extended-wear contact lenses. In addition, the invention provides a method for making a medical device, preferably a contact lens, having an antimicrobial coating thereon. | 2008-10-23 |
20080260805 | THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity. | 2008-10-23 |
20080260806 | Personal hygiene compositions and methods - A personal hygiene composition, which may be coated on a towelette, comprises an astringent, a humectant, and a botanical extract. In some embodiments, the botanical extract can be selected from the group consisting of | 2008-10-23 |
20080260807 | Water-Soluble Films Comprising Nicotine - A water-soluble film comprising nicotine, wherein said nicotine may be any pharmacologically effective form of nicotine present at one or more locations of the film defined by the application of a nicotine-containing fluid to at least one surface of a preformed water-soluble film. | 2008-10-23 |
20080260808 | DEVICE FOR SMOOTHING WRINKLES ON HUMAN SKIN - Device for smoothing wrinkles on human skin and for enabling skin sections between successive wrinkles to achieve prolonged contact with cosmetic and/or pharmaceutical substances carried by said device. | 2008-10-23 |
20080260809 | POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 2008-10-23 |
20080260810 | Hemostat - The present invention is directed towards a hemostat comprising an absorbable foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen. | 2008-10-23 |
20080260811 | Transdermal delivery systems - Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided. | 2008-10-23 |
20080260812 | Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) - An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis. | 2008-10-23 |
20080260813 | PHARMACEUTICAL COMPOSITION OF TOPIRAMATE - The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described. | 2008-10-23 |
20080260814 | INJECTION MOULDING PROCESS FOR NEUTRAL AND ACID-GROUP-CONTAINING (METH)ACRYLATE COPOLYMERS - Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold. | 2008-10-23 |
20080260815 | Multiparticulates - Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit® RSPO, a plasticising excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit® RLPO. The obtained multiparticulates show a release rate profile which is pH-independent. | 2008-10-23 |
20080260816 | Particulate Lipid Pharmaceutical Composition - A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media. Also disclosed is a method of producing the composition and a tablet containing it; sachets and capsules filled with the composition; use of the composition and the tablet as a medicine; a method of administering the composition to a patient. | 2008-10-23 |
20080260817 | Compositions for the Treatment of Inflammation and Pain Using a Combination of a Cox-2 Selective Inhibitor and a Ltb4 Receptor Antagonist - The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB | 2008-10-23 |
20080260818 | Controlled Absorption of Statins in the Intestine - The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet. | 2008-10-23 |
20080260819 | SUSTAINED RELEASE COMPOSITIONS OF DRUGS - A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles coated with one or more coating layers. The sustained release composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chewing or crushing) and the resulting material is placed in 0.1N HCl. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of diffusion, surfactant action of bile acids, mechanical erosion, and in some embodiments, enzymatic degradation. | 2008-10-23 |
20080260820 | Oral dosage formulations of protease-resistant polypeptides - Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions that are treatable or preventable by the administration of such oral dosage formulations of protease-resistant polypeptides are provided. | 2008-10-23 |
20080260821 | Berry Preparations and Extracts - A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4.5, and recovering a berry extract having a stabilized anthocyanin content. The berry may be a blackberry. A cryoprotectant may be added, to further stabilize the anthocyanin content. Compositions comprising the berry extract of the present invention, formulated for oral and/or topical administration, are provided also, including nutritional supplements, capsules, enteric-coated capsules, film-coated capsules, tablets, enteric-coated tablets, film-coated tablets, chewing gums, lotions, creams, mucoadhesive gels, vanishing lotions, vanishing creams, and the like. In yet another aspect, the present invention provides methods and compositions for treating inflammation, oxidative damage, or cancer in a mammal. | 2008-10-23 |
20080260822 | SYNTHESIS OF HUMAN SECRETORY IgA AND IgM AND THE FORMATION OF A MEDICAMENT THEREFROM - A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of | 2008-10-23 |
20080260823 | ORALLY DISINTEGRATING TABLET COMPRISING GLYCOPYRROLATE FOR TREATING SIALORRHEA - The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate to the patient. | 2008-10-23 |
20080260824 | Bioadhesive Rate-Controlled Oral Dosage Formulations - The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner. Also described herein are polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers. | 2008-10-23 |
20080260825 | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2008-10-23 |
20080260826 | Pharmaceutical composition and process - The present invention relates to a method of forming granules of (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate; hydrochloride salt (I), comprising mixing I, with a granulating amount of a granulating liquid, and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer as a binder and solubility enhancer to form wet granules which are then dried to remove the granulating liquid. | 2008-10-23 |
20080260827 | RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE - A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three consecutive days per month is useful for treating or preventing osteoporosis and other bone metabolic disorders. | 2008-10-23 |
20080260828 | STABLE SOLID DISPERSION OF A DERIVATIVE OF VINCA ALKALOID AND PROCESS FOR MANUFACTURING IT - This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000. | 2008-10-23 |
20080260829 | Bmp Gene and Fusion Protein - This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions. | 2008-10-23 |
20080260830 | Growth Factor Mutants With Improved Biological Activitiy - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity. | 2008-10-23 |
20080260831 | Extracellular Matrix-Derived Gels and Related Methods - Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. | 2008-10-23 |
20080260832 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION - Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure. | 2008-10-23 |
20080260833 | Drug delivery vehicle containing vesicles in a hydrogel base - A drug delivery vehicle having active agent loaded vesicles in a hydrogel matrix; desirably either or both of the vesicles and matrix are made of at least one stimulus responsive polymer so that active agent is released in response to contact with a stimulus. | 2008-10-23 |
20080260834 | VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS - Localized delivery of 1,25 D | 2008-10-23 |
20080260835 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension. | 2008-10-23 |
20080260836 | Films Comprising a Plurality of Polymers - Films are disclosed that comprise a first polymer and a second polymer having a solubility temperature lower than that of the first polymer; wherein the breaking strength of the film is greater than about 750 psi (5,171 kPa). Also disclosed are compositions comprising such films that are useful as oral care, personal care or home care compositions. Methods of using such compositions are also disclosed. | 2008-10-23 |
20080260837 | Physically stable aqueous suspensions of active pharmaceuticals - The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water. | 2008-10-23 |
20080260838 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS - A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery. | 2008-10-23 |
20080260839 | Pulmonary Formulation - The use of microparticles of silicon and particularly resorbable and/or photoluminescent silicon in the preparation of a medicament for nasal or pulmonary delivery. Aerosol formulations and their preparation are also described and claimed. These formulations may be used for example as carriers for pharmaceutical compounds as well as having diagnostic applications. | 2008-10-23 |
20080260840 | Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described. | 2008-10-23 |
20080260841 | Micronized wood preservative formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood. | 2008-10-23 |
20080260842 | PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics. | 2008-10-23 |
20080260843 | TRANSPULMONARY COMPOSITION - It is an object of the present invention to provide a transpulmonary preparation wherein physiologically active ingredient can be stably retained and which has high absorption efficacy and gives low damage to tissue. The present invention provides a transpulmonary preparation which comprises protein nanoparticles containing an active ingredient and having an average particle size of 200 nm to 500 nm. | 2008-10-23 |
20080260844 | Solid, Oral, Microparticulate Dosage Form Which Has Been Designed To Prevent Misuse - The invention relates to the field of solid, oral, microparticulate dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient contained therein. The aim of the invention is to prevent the improper use of solid oral medicaments for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characterised in that at least one part of the active pharmaceutical ingredient is contained in the microparticles thereof and in that the inventive form comprises anti-crushing means which are intended to impede or completely prevent the crushing of the microparticles of the active pharmaceutical ingredient, such as to preclude the misuse thereof. | 2008-10-23 |
20080260845 | MULTIPLE ACTIVE DRUG RESIN CONJUGATE - A combination pharmaceutical preparation including two different active drugs of the same ionic charge conjugated with a single resin particle, without one significantly displacing the other, and without retarding the initial availability of either active. Also, methods for the manufacture of a multiple active drug-resin conjugate, and for the in vivo release of a combination of pharmaceutically active drugs from a multiple active drug-resin conjugate. | 2008-10-23 |
20080260846 | Long Acting Sustained-Release Formulation Containing Dopamine Receptor Agonist and the Preparation Method Thereof - The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight. | 2008-10-23 |
20080260847 | Polymer-Based Sustained Release Device - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 2008-10-23 |
20080260848 | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration - Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs. | 2008-10-23 |
20080260849 | COMPOSITION FOR TRANSMUCOSAL ABSORPTION - It is an object of the present invention to provide a composition for transmucosal absorption which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high transmucosal absorbability. The present invention provides a composition for transmucosal absorption which comprises protein nanoparticles containing an active ingredient and having an average particle size of 10 nm to 300 nm. | 2008-10-23 |
20080260850 | Delivery System For Bioactive Agents on the Basis of a Polymeric Drug Carrier Comprising an Amphiphilic Block Polymer and a Polylacticacid Derivative - Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or trivalent metal ion, which is obtained by adding the di- or trivalent metal ion to the polymeric composition. | 2008-10-23 |
20080260851 | Polymeric Nanoparticles and Nanogels for Extraction and Release of Compounds - The invention relates to polymeric nanoparticles and nanogels, which can contain, deliver, and/or release one or more active agents, such as biologically active molecules or fragrance molecules, and methods of preparing the polymeric nanoparticles and nanogels. The nanoparticles are crosslinked utilizing radiation (g-radiation) as the catalyst for free radical polymerization (see FIG. | 2008-10-23 |
20080260852 | SUPERCRITICAL FLUID EXTRACTION PRODUCED BY IN-LINE HOMOGENIZATION - A method for producing micro and/or nanoparticles by contacting an emulsion with a supercritical fluid. The method can be used to produce an aqueous suspension of particles that include a drug encapsulated in a polymer. The drug and polymer are dissolved in an organic solvent to form an organic solution. The organic solution is pumped into contact with an aqueous solution in an in-line homogenization device to form an emulsion. Immediately after the emulsion in the in-line homogenization device, the emulsion contacts the supercritical fluid. The supercritical fluid extracts the organic solvent from the oil droplets of the emulsion, causing the drug and polymer to precipitate into the aqueous phase of the emulsion and thereby form an aqueous suspension of particles that include a drug encapsulated in a polymer. | 2008-10-23 |
20080260853 | EXTRACELLULAR MATRIX AS SURGICAL ADJUNCT IN A LUMPECTOMY PROCEDURE - The invention an article or composition of mammalian extracellular matrix (ECM) for placement in a lumpectomy space of a breast after tumor removal. The extracellular matrix article or composition can regenerate lost breast tissue, reduce the formation of scar tissue at the site of excision, and reduce a likelihood of local tumor recurrence at the lumpectomy site. The article can be sheet ECM, and the composition can be particulate ECM or emulsion or gel ECM. | 2008-10-23 |
20080260854 | Sirna Molecules for the Treatment of Blood Vessels - The present invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition which comprises the nucleic acid molecule and/or the genetic construct and/or the siRNA molecules and can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a device, which is coated with the aforementioned molecules, the composition or the construct, or contains them. The present invention further relates to a corresponding use of the nucleic acid molecule, of the genetic construct or of the siRNA molecules and a method of inhibition of the expression of adhesion molecules and a method of vessel grafting, lung transplantation, treatment of lung transplants, and a method of treatment of the open heart within the scope of cardioplegia. | 2008-10-23 |
20080260855 | Processed water and therapeutic uses thereof - A physiologically ingestible composition of matter obtained by preparing oxygenated water with a stable negative oxidation reduction potential (ORP), and the uses thereof, are provided. The obtaining method includes preconditioning water received from a water source for electrolysis, performing electrolysis on the preconditioned water, outputting alkaline water and/or acidic water with a stable negative ORP (“negative ORP water”), combining the negative ORP water with oxygen, and manipulating the combined negative ORP water and oxygen into a vortex so as to cause the oxygen to diffuse into the water. The output alkaline and/or acidic oxygenated water with a stable negative ORP may be used for a variety of purposes and/or applications. For example, the method may be utilized as part of a method for producing and tuning super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to treat infection in a mammal. | 2008-10-23 |
20080260856 | Topical composition containing sacred water - Topical compositions having as at least one part of their composition sacred and/or holy water. These compositions are useful for imparting a spiritual sense of well-being. | 2008-10-23 |
20080260857 | Substance and Method for Treating Neoplasms - The invention relates to substance and method for treating neoplasms in mammals. A substance for treating neoplasm comprises water comprising from 99.76 to 99.99 molecular % of light isotopologue | 2008-10-23 |
20080260858 | Universal Procoagulant - A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching a metal binding domain, such as an oligohistidine tag, to the C-terminus of sTF allows the protein to bind to phospholipid vesicles that contain metal-chelating lipid. Metal complexes of this activated sTF and metal-chelating lipids have all of the desirable expression, handling, and solubility characteristics of sTF, and exhibit procoagulant activities in plasma clotting tests that are comparable to relipidated rTF. In addition, it was discovered that, under some circumstances, Ni-lipids are themselves procoagulant, even in the absence of activated sTF. Further studies indicated that Ni-lipids are potent activators of the contact pathway of blood clotting. | 2008-10-23 |
20080260859 | Composition Containing Omega-3 Fatty Acids and Omega-6 Fatty Acids - A composition comprises at least an omega-3 fatty acid, at least an omega-6 fatty acid, and zinc. The composition is advantageously administered to a subject suffering from a condition of dry eye. In certain embodiment, the amount of omega-3 fatty acid is much higher than that of the omega-6 fatty acid. | 2008-10-23 |
20080260860 | Method for the Acaricidal Finishing of Textile Materials - The use is described of zinc pyrithione for finishing woven and non-woven textiles to render them resistant against colonization by house dust mites. Zinc pyrithione is used alone or in combination with other actives with or without other textile chemicals. The formulations comprising zinc pyrithione are applied to the textiles using the standard processes of textile finishing, such that there is a concentration of preferably 1000 to 6000 ppm of zinc pyrithione on the textile. This gives on uncoated sheetlike textiles a very distinct reduction in the mite population in testing; ideal finishes even eliminate the mite population completely. | 2008-10-23 |
20080260861 | Modulating Lymphatic Function - Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed. | 2008-10-23 |
20080260862 | Composition for treatment and prevention of bone loss - The composition set forth provides for the prevention and treatment of bone loss and osteoporosis. The formulation combines Vitamin D; Calcium Citrate Malate; Potassium Citrate; Magnesium; Boron and Vitamin K. Each component has an effect on its own combined with a synergistic effect with the other components. | 2008-10-23 |
20080260863 | COMPOSITIONS FOR MUCOCILIARY CLEARANCE AND METHODS FOR ADMINISTERING SAME - Sterile, preservative-free premeasured hypertonic saline solutions may be administered to individuals afflicted with cystic fibrosis to increase mucolciliary clearance and to improve lung function. In particular, a 7% hypertonic saline solution may be administered at least 2 times a day, using a jet and/or vibrating-mesh nebulizer to an individual afflicted with cystic fibrosis. | 2008-10-23 |
20080260864 | Topical Compositions for the Treatment of Depilation-Induced Irritation or Prevention Thereof - The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present invention consists of a method for prevention and/or treatment of skin irritation induced by depilation. | 2008-10-23 |
20080260865 | Methods for Treating Bacterial Respiratory Tract Infections in an Individual Using Acidified Nitrite - Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant | 2008-10-23 |
20080260866 | Method for decreasing inflammation and stress in a mammal - The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite. | 2008-10-23 |
20080260868 | Folate based composition for neurological and cognitive applications - New formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, particularly Alzheimer's Disease comprise folate in combination with compounds chosen to address some or all of the pathways which can result in neurological deficiencies and diseases, namely inflammation, oxidative stress, glycation/dysinsulinemia, platelet function, homocysteine levels and acetylcholinesterase inhibition, that are important contributors to the development or progression of AD. | 2008-10-23 |
20080260869 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS - Disclosed is a composition comprising at least two of the following ingredients: Magnolia extract, honokiol, | 2008-10-23 |
20080260870 | COMPOSITIONS FOR PROTECTING LIVER, OR FOR PREVENTING OR TREATING LIVER FIBROSIS OR CIRRHOSIS - Disclosed is a composition for hepatoprotection, or for prevention or treatment of liver fibrosis or cirrhosis, which comprises as an active ingredient a water extract of a mixture of | 2008-10-23 |
20080260871 | METHOD AND COMPOSITION FOR INFUSING HERBAL EXTRACTS AND PHARMACEUTICALS THROUGH THE SKIN - A topical mixture, that when massaged onto the skin, enables infusion of drugs or herbal compounds into deeper tissues, and a method of enhancing the penetration and concentration of drugs and herbs into tissues, especially as relates to treatment of pain. | 2008-10-23 |
20080260872 | Gro-protect solutions - The components of Gro-Protect Solutions is a liquid protective growth serum, which protects the natural hair from the harmful effects of hair gluing products along with special conditioners that promotes and allows natural hair growth. | 2008-10-23 |
20080260873 | Agent for prevention or improvement of neuropathy comprising pre-germinated brown rice lipid fraction as an effective ingredient - The present invention is intended to find a novel function of a component in pre-germinated brown rice and to provide a safe and effective agent or functional food for prevention or improvement of a neuropathy or diabetic neuropathy | 2008-10-23 |
20080260874 | Peripheral Blood Flow-Improving Composition - The present invention provides a composition that can effectively improve peripheral blood flow to thereby ameliorate cold sensation, numbness, pains and other skin symptoms, as well as frostbites, chilblains and chaps and other skin disorders associated with disturbed peripheral blood flow. This composition has no side effects. Specifically, the peripheral blood flow-improving composition contains, as an active ingredient, a extract of a plant of the genus | 2008-10-23 |
20080260875 | NOVEL SKIN CARE COMPOSITIONS AND METHODS - Skin care compositions and methods are provided comprising a highly hydrophobic substance, an alkaryl polyfluorocarbon, particularly a substituted phenyl-polyfluoroacylamino propanamide, an alkanol and refined oils and the oil triglyceride fractions in sufficient amount to provide substantial homogeneity. When employed for hirsutism, optionally antioxidants and moisturizer are added. For use against wrinkles, additionally vitamins, antioxidants and a mixture of extracts of naturally occurring substances are present. | 2008-10-23 |
20080260876 | Garlic Extract Compositions, Uses And Preparations Thereof - The present invention relates to compositions comprising a garlic extract and chitosan or a salt thereof. These compositions present an enhanced antifungal activity, or activity for controlling powdery mildew disease, in various types of plants, vegetables, fruits or flowers, particularly when compared to garlic extract alone or to chitosan or a salt thereof alone. These compositions also present an extended shelf life when compared to garlic extract alone. Methods for preparing such compositions and methods for using them are also disclosed. | 2008-10-23 |
20080260877 | Plant extracts and compositions for reducing blood lipid levels - An extract of a plant of the genus | 2008-10-23 |
20080260878 | Composition for Prevention or Alleviation of Pigmentation - A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with (B) at least one member selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinols, linoleic acid, tranexamic acid, salts of these, Chamomilla recuita extract, and Ubiquinone. | 2008-10-23 |
20080260879 | Use of Paeonia and Extracts Thereof with Growth Promoting Activity in Veterinary Medicine and Zootechnics - The present invention relates to the use of extracts of plants or roots of the | 2008-10-23 |
20080260880 | Oral Compositions for the Prevention of Uv Damages - The invention relates to oral compositions for the prevention of UV damages, in particular to oral compositions based on an olive extract obtained by extracting vegetation water from olive pressing with an organic solvent or by extracting olive cake with water and/or an organic solvent. | 2008-10-23 |
20080260881 | Blue-green algae composition - A broad spectrum functional food formulation based on blue-green algae and concentrated extracts of blue-green algae provides numerous health benefits when orally administered in therapeutically effective amounts. Whole aphanizomenon flos-aqua is combined with concentrates of phycocyanin and phenylethylamine to provide a life-enhancing dietary supplement which can stimulate stem cell production, elevate mood and reduce inflammation and joint pain. | 2008-10-23 |
20080260882 | CUTTING MACHINE - The present invention relates to a cutting machine comprising at least one moving type cutting table ( | 2008-10-23 |
20080260883 | Plant for Producing Slabs of Conglomerate Stone Material - In a plant for manufacturing conglomerate sheets comprising a first station ( | 2008-10-23 |